Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers

Vaccine

Volumn 14, Issue 12, 1996, Pages 1111-1117

  Von Specht, Bernd Ulrich ^a   Lücking, Hanns Christian ^a   Blum, Barbara ^b   Schmitt, Anja ^a   Hungerer, Klaus Dieter ^c   Domdey, Horst ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Forschungslaboratorien der B   (Germany)

Author keywords

C1q; Outer membrane protein; P. aeruginosa; Vaccine

Indexed keywords

OUTER MEMBRANE PROTEIN; PSEUDOMONAS VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

EID: 0030581389     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(96)00054-0     Document Type: Article

References (44)

1. 1 Gallagher, P.G. and Watanakunakorn, Ch. Pseudomonas bacteremia in a community teaching hospital, 1980-1984. Rev. Infect. Dis. 1989, 11, 846-852
2. 2 Griffith, S.J., Nathan, C., Selander, R.K. and Chamberlin, W. Gordon, St., Kabins, S. and Weinstein, R.A. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital. J. Infect. Dis. 1989, 160, 1030-1036
3. 3 Korvick, J.A., Marsh, J.W., Starzl, T.E. and Yu, V.L. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: an emerging problem. Surgery 1991, 109, 62-68
4. 4 Pruitt, B.A.Jr. and McManus, A.T. Opportunistic infections in severely burned patients. Am. J. Med. 1984, 76Suppl 3A, 146-154
5. 5 McManus, A.T., Mason, A.D.Jr., McManus, W.F. and Pruitt, B.A.Jr. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur. J. Clin. Microbiol. 1985, 4, 219-223
6. 6 Holzheimer, R.G., Quoika, P., Pätzmann, D. and Füssle, R. Nosocomial infections in general surgery: Surveillance Report from a German University Clinic. Infect. 1990, 18, 219-225
7. 7 Hancock, R.E.W. Intrinsic antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 1986, 18, 653-656
8. 8 Zak, O. Antibiotics and Pseudomonas aeruginosa. In: Pseudomonas aeruginosa International Symposium, Huber, Bern, (Eds. Sabath, L.D. et al.) 1980, pp, 133-159
9. 9 Holder, I.A. Pseudomonas immunotherapy. Serodiagn. lmmunother. 1988, 2, 7-16
10. 10 Pennington, J.E. Pseudomonas aeruginosa. Vaccines and immunotherapy. Infect. Dis. Clin. North Am. 1990, 4, 259-270
11. 11 Alexander, J.W. and Fisher, M.W. Immunization against Pseudomonas infection after thermal injury. J. Infect. Dis. 1974, 130, S152-S158
12. 12 Miller, J.M., Spilsbury, J.F., Jones, R.J., Roe, E.A. and Lowbury, E.J.L. A new polyvalent Pseudomonas vaccine. J. Med. Microbiol. 1977, 10, 19-27
13. 13 Jones, RJ., Roe, E.A. and Gupta, J.L. Controlled trials of a polyvalent Pseudomonas vaccine in burns. Lancet 1979, 2, 977-983
14. 14 Cryz, S.J.Jr., Sadoff, J.C. and Fürer, E. Octavalent Pseudomonas aeruginosa-O-polysaccharide-toxin A conjugate vaccine. Microb. Pathogen. 1987, 6, 75-80
15. 15 Cryz, S.J.Jr., Fürer, E., Cross, A.S., Wegmann, A., Germanier, R. and Sadoff, J.C. Safety and immunogenicity of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine in humans. J. Clin. Invest. 1987, 80, 51-56
16. 16 Pier, G.B. Safety and immunogenicity of high-molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa. J. Clin. Invest. 1982, 69, 303-308
17. 17 Pier, G.B. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research. In: Pseudomonas aeruginosa: new therapeutic approaches from basic research (Eds Speert, D.P. and Hancock, R.E.W.) vol 36, pp. 157-167, S. Karger, Basel.
18. 18 Pier, G.B., des Jardin, D., Grout, M., Garner, C., Bennet, S.E., Pekoe, G. et al. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect. Immun. 1994, 62, 3972-3979
19. 19 Mutharia, L.M., Nicas, T.I. and Hancock, R.E.W. Outer membrane proteins of P. aeruginosa serotype strains. J. Infect. Dis. 1982, 146, 770-779
20. 20 von Specht, B.-U., Strigl, G., Ehret, W. and Brendel, W. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection. Infection 1987, 15, 408-412
21. 21 Duchêne, M., Schweizer, A., Lottspeich, F., Krauss, G., Marget, M., Vogel, K., von Specht, B.-U. and Domdey, H. Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene. J. Bacteriol. 1988, 170, 155-162
22. 22 Duchêne, M., Barren, C., Schweizer, A., von Specht, B.-U. and Domdey, H. Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning,sequence, and expression in Escherichia coil. J. Bacteriol. 1989, 171, 4130-4137
23. 23 Finke, M., Duchêne, M., Eckhardt, A., Domdey, H. and von Specht, B.-U. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infect. Immun. 1990, 58, 2241-2244
24. 24 Finke, M., Muth, G., Reichhelm, T., Thoma, M., Duchêne, M., Hungerer, K.-D., Domdey, H. and von Specht, B.-U. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies. Infect. Immun. 1991, 59, 1251-1254
25. 25 von Specht, B.-U., Knapp, B., Muth, G., Bröker, M., Hungerer, K.-D., Diehl, K.-D., Massarrat, K., Seemann, A. and Domdey, H. Protection of immunocompromised mice against lethal infection with P. aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect. Immun. 1995, 63, 1855-1861
26. 26 Kraehenbuhl, J.P. and Neutra, M.R. Molecular and cellular basis of immune protection of mucosal surfaces. Physiol. Rev. 1992, 72, 853-879
27. 27 Buret, A.M.L., Dunkley, G., Pang, R.L., Clancy, D. and Cripps, A.W. Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats: Roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1a. Infect. Immun. 1994, 62, 5335-5343
28. 28 Toth, A., Schödel, F., Duchêne, M., Massarrat, K., Blum, B., Schmitt, A., Domdey, H. and von Specht, B.-U. Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin. Vaccine 1994, 12, 1215-1221
29. H1 cells trigger tumor necrosis factor alpha -mediated hypersensitivity to P. aeruginosa after adoptive transfer into SCID mice. Infect. Immun. 1995, 63, 1107-1112
30. 30 Cohen, J. Naked DNA points way to vaccines. Science 1993, 259, 1691-1692
31. 31 Donnelly, J.J. Ulmer, J.B. and Liu, M.A. Immunization with polynucleotides. The Immunologist 1994, 2, 20-26
32. 32 Eckhardt, A., Heiss, M.M., Ehret, E., Permanetter, W., Duchêne, M., Domdey, H. and von Specht, B.-U. Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay. Zbl. Bakt. 1991, 275, 100-111
33. 33 Høiby, N. and Koch, C. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 1990, 45, 881-884
34. 34 Johansen, H.K. and Høiby, N. Seasonal onset of initial colonization and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 1992, 47, 109-111
35. 35 Schein, O.D., Lynn, R.J., Poggio, E.C., Seddon, J.-M. and Kenon, K.R. . The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. N. Engl. J. Med. 1989, 321, 773-778
36. 36 Gilligan, P.H. Microbiology of airways disease in patients with cystic fibrosis. Clin. Microbiol. Rev. 4, 35-51.
37. 37 Lawin-Brussel, C.A., Refojo, M.F., Leong, F.L., Hanninen, L. and Kenyon, K.R. Time course of experimental Pseudomonas aeruginosa keratitis in contact lens overwear. Arch. Ophthalmol. 1990, 108, 1012-1019
38. 38 Banerjee, S.N., Emori, T.G., Culver, D.H., Gaynes, R.P., Jarvis, W.R., Horan, T., Edwards, J.R., Tolson, J., Henderson, T. and Martone, W.J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am. J. Med. 1991, 91Suppl.3B, 86S-89s
39. 39 Hatano, K., Goldberg, J.B. and Pier, G.B. Biologic activities of antibodies to the neutral-polysaccharide component of Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate). Infect. Immun. 1995, 63, 21-26
40. 40 Takacs, BJ. and Girard, M.F. Preparation of clinical grade proteins produced by recombinant DNA technologies. J. lmmunol. Methods 1991, 143, 231-240
41. 41 Baker, C.J., Edwards, M.S. and Kasper, D.L. lmmunogenicity of polysaccharides from type III, group B Streptococcus. J. Clin. Invest. 1978, 61, 1107
42. 42 Greenberg, D.P., Vadheim, C.M., Bordenave, N., Ziontz, L., Christenson, P., Waterman, S.H. and Ward, J.I. Protective efficacy of Haemophilus influenzae type b polysaccharide and conjugate vaccines in children 18 month of age and older. JAMA 1991, 265, 987-992
43. 43 Cryz, S.J. Jr., Sadoff, C., Ohmann, D. and Fürer, E. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. J. Lab. Clin. Med. 1988, 111, 701-707
44. 44 Hong, Y.Q. and Ghebrehiwet, B. Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3. Clin. Immun. and lmmunopath. 1992, 62, 1333-1338